Indaptus Therapeutics Insider Trades
NASDAQ: INDPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 0 · $0
- Shares bought / sold
- 0 / 0
- Net activity
- Net buying $0
Indaptus Therapeutics insider activity
Over the last 12 months, Indaptus Therapeutics insiders reported 5 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows Ben-Tzvi Avraham (Director) reporting a transaction in 25,000 shares on Jan 20, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put INDP's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
INDP insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jan 20, 2026 | Ben-Tzvi AvrahamDirector | Award | 25,000 | — | Form 4 |
| Dec 22, 2025 | Linscott Walt AddisonChief Operating Officer | Award | 54,421 | $110.47K | Form 4 |
| Dec 22, 2025 | Newman Michael JamesCSO and Director | Award | 52,204 | $105.97K | Form 4 |
| Dec 22, 2025 | Meckler Jeffrey ACo-Chief Executive Officer | Award | 216,617 | $439.73K | Form 4 |
| Dec 22, 2025 | Sassi NirChief Financial Officer | Award | 26,758 | $54.32K | Form 4 |
| Jul 27, 2025 | Meckler Jeffrey AChief Executive Officer | Award | 6,068 | $50.38K | Form 4 |
| Nov 25, 2024 | Meckler Jeffrey ACEO and Director | Award | 42,553 | $50.00K | Form 4 |
| Aug 8, 2024 | Meckler Jeffrey ACEO and Director | Award | 84,932 | $155.00K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4